Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.56 |
| ▸ | CCR5 | P51681 | 6/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TEC | P42680 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25243438 | 0.84 | MAOB (0.49) | MAOBCCR5MAOA | |
| SCHEMBL25692168 | 0.83 | MAOB (0.69) | MAOBAPPMAOAALOX5 | |
| SCHEMBL1376230 | 0.83 | ALOX5 (0.73) | MAOBAPPMAOAALOX5NR4A2 | |
| SCHEMBL29576561 | 0.83 | ALOX5 (0.73) | MAOBMAOAALOX5 | |
| SCHEMBL2636350 | 0.83 | ALOX5 (0.73) | MAOBMAOAALOX5 | |
| SCHEMBL13321706 | 0.79 | MAOB (0.55) | MAOBCCR5APPMAOANR4A2 | |
| SCHEMBL22407066 | 0.78 | MAOB (0.54) | MAOBAPPMAOANR4A2 | |
| SCHEMBL10991891 | 0.78 | MAOB (0.80) | MAOBAPPMAOANR4A2 | |
| SCHEMBL25232253 | 0.77 | MAOA (0.47) | MAOBMAOA | |
| SCHEMBL31533149 | 0.77 | MAOB (0.60) | MAOBAPPMAOANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118715015-A | Selective PHD1 inhibitor compounds, compositions and methods of use | 阿克比治疗有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN1, EGLN2 | MAOB 2760/4885CCR5 4384/4885APP 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.